Inclusion Criteria:

          -  Subjects must have histologically confirmed diagnosis of non-Hodgkin?s lymphoma that
             has relapsed, or is refractory, after upfront induction therapy. Excluded histologies
             are T-cell lymphomas, post-transplant lymphoproliferative disorder, Burkitt lymphoma,
             lymphoblastic lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma. All
             other histologies are eligible that include but not limited to: diffuse-large B-cell
             lymphoma, follicular lymphoma (grades I, II, and III), marginal zone lymphoma,
             transformed indolent lymphoma, grey zone lymphoma, and undifferentiated B-cell
             lymphoma. Patients with non-Hodgkin's lymphoma (NHL) who are at high risk of relapse
             can be enrolled in sustained partial response (PR) after induction chemotherapy (PR1)

          -  Expected survival of more than six months

          -  Karnofsky performance status >= 80%

          -  Within 1 week prior to initiation of treatment: Aspartate aminotransferase
             (AST)/alanine aminotransferase (ALT) < 3 x upper limits of normal (ULN) unless due to
             disease

          -  Within 1 week prior to initiation of treatment: Total bilirubin < 2 x ULN unless due
             to disease

          -  Within 1 week prior to initiation of treatment: Calculated glomerular filtration rate
             (GFR) 30 ml/min

          -  Within 1 week prior to initiation of treatment: Absolute neutrophil count (ANC) > 500
             cells/mm^3

          -  Within 1 week prior to initiation of treatment: Platelet count > 50 mm^3

          -  Left ventricular ejection fraction >= 40%

          -  Diffusion capacity of carbon monoxide (DLCO) >= 50% predicted

          -  Ability to collect 2 x 10^6/kg CD34+ cells for transplantation

          -  Patient must be otherwise eligible for autologous stem cell transplantation (ASCT) per
             local institutional guidelines

          -  No serious disease, or condition, that, in the opinion of the investigator, would
             compromise the patient?s ability to participate in the study

          -  Subjects must have the ability to understand and the willingness to sign a written
             informed consent document

        Exclusion Criteria:

          -  Subjects who sustained a complete metabolic response (CMR) by positron emission
             tomography (PET)-computed tomography (CT) (Deauville score of =< 3) after salvage
             chemotherapy unless lymphoma relapsed less than 12 months from the first day of last
             cycle of induction chemotherapy OR patient required more than 2 lines of salvage
             chemotherapy to sustain a CMR

          -  Subjects receiving any other investigational agents

          -  Prior treatment with venetoclax

          -  Patients with central nervous system (CNS) involved by lymphoma can be included if CNS
             disease is deemed controlled prior to enrollment as determined by the investigator.
             Patients with uncontrolled CNS disease will be excluded

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to venetoclax or other agents used in this study

          -  Subjects with uncontrolled intercurrent illness including, but not limited to ongoing
             or active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Patients who are human immunodeficiency virus (HIV) positive and receiving combination
             antiretroviral therapy will be excluded; because of the potential for pharmacokinetic
             interactions with venetoclax

          -  Female patients who are pregnant or breast-feeding. Confirmation that the subject is
             not pregnant must be established by a negative serum beta-human chorionic gonadotropin
             (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not
             required for post-menopausal or surgically sterilized women. Male or female patients,
             who are sexually active and of the child bearing age, must be willing to practice
             accepted birth control measures